Logo yposkesi
waves image

About us

Team Yposkesi CDMO

Best-in-Class CDMO

The Yposkesi story begins in 1990 with the AFM-Telethon, the French Muscular Dystrophy Association, and a mission to make innovative therapies accessible to patients with genetic disorders and other disabilities. After years of genome research and clinical trials in humans, the association decides to develop a viral vector manufacturing facility to accelerate the time to market for gene therapies: Yposkesi is created in 2016. Leveraging this unique expertise and knowledge, Yposkesi become a pioneer in his field. Since March 2021, Yposkesi welcomed SK Inc. as its main shareholder. With this new partnership, Yposkesi becomes a member of SK pharmteco, a global CDMO player with 80 years of experience. With operations including 7 cGMP manufacturing and development facilities across the United States, Korea, Ireland, and France, SK pharmteco is bringing to Yposkesi a global presence with advanced technologies.

pharma gene therapy factory

Yposkesi's story

The Yposkesi story begins with the AFM-Telethon, the French Muscular Dystrophy Association, and a mission to make innovative therapies accessible to patients with genetic disorders and other disabilities. AFM-Telethon had originally created Genethon and CECS/I-Stem, two-world-class R&D centers developing respectively gene and cell therapies for orphan genetic diseases from research to clinical validation, with an early focus on biomanufacturing since 2006. Leveraging this unique expertise and knowledge, Yposkesi was launched in November 2016. Since March 2021, Yposkesi welcomed SK Inc., as its main shareholder.

Yposkesi building

Our facilities

Located in the Genepole Innovation campus in Corbeil-Essonnes (South of Paris) in France, Yposkesi’s current 50,000 ft2 (approx. 5,000m2) facility operates multiple manufacturing suites for bulk drug substance (up to 1,000L) and Fill & Finish to support the growing demand for late-phase projects.
In order to accelerate the time to market for cell and gene therapies, Yposkesi is currently building an extension of its facility, designed for EMA and FDA compliance that will increase its global footprint to 100,000 ft2 (approx. 10,000m2) in 2023. This state-of-the-art extension will path the way toward commercialization and help us meet our client’s timeline and budget.

Viral vector manufacturing

Viral vector manufacturing in one of Europe’s largest facilities

Being a pioneer in his field, Yposkesi is one of the largest AAV and lentiviral vectors production facility in Europe. With our facilities expanding by 2023, this will further be strengthening Yposkesi’s lead.
We know that time is of essence in clinical development of new therapies, and manufacturing is often a bottleneck for gene therapy manufacturers. The sheer size of our cGMP facility, dedicated technical team, and expertise enable us to readily accommodate new projects and meet the on-time demands of our clients breaking ground in therapeutic treatments.

Our services